

**PerCP Anti-human CD22 Antibody \*HIB22\***Catalog number: 102201T0, 102201T1, 102201T2  
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

---

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

**Antibody Properties**

---

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Isotype	Mouse IgG1
Immunogen	CD22 (BL-CAM, Siglec-2)
Clone	HIB22
Conjugate	PerCP

**Biological Properties**

---

Preparation	Antibody purified by affinity chromatography and then conjugated with PerCP under optimal conditions
Application	Flow Cytometry (FACS)

**Spectral Properties**

---

Conjugate	PerCP
Excitation Wavelength	477 nm
Emission Wavelength	678 nm

**Applications**

---

HIB22 is an anti-human monoclonal antibody that recognizes the CD22 antigen. CD22 (also known as BL-CAM or Lyb8) is a 120 - 130 kD glycoprotein that is located on the surface of cells like B cells and stem cells. CD22 plays a role in essential cellular pathways, namely, the negative regulation of B cell receptor signaling pathway. Moreover, in many organisms, it is a negative regulator of calcium-mediated signaling, suppresses immunoglobulin secretion and is involved in the negative regulation of B cell receptor signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands like PI3-kinase, PLCg1, p53/56lyn and CD45. CD22 is a fairly uncommon antibody target, with a little more than 4000 publications in the last decade. Even still, CD22 is vital to cell biology research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through

affinity chromatography and conjugated to PerCP (ex/em = 477/678 nm). It is compatible with the 488 nm laser and 667/30 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte Advanteon).